# A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

> **NCT06939452** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yongxu Jia** · enrollment: 37 (estimated)

## Conditions studied

- Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

## Interventions

- **DRUG:** anlotinib +TQB2450 + Oxaliplatin+S-1

## Key facts

- **NCT ID:** NCT06939452
- **Lead sponsor:** Yongxu Jia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-07
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06939452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06939452, "A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06939452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*